KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to $27.9 million.

  • Rigel Pharmaceuticals' Profit After Tax rose 12461.96% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.3 million, marking a year-over-year increase of 281935.07%. This contributed to the annual value of $17.5 million for FY2024, which is 16968.63% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Profit After Tax stood at $27.9 million for Q3 2025, which was up 12461.96% from $59.6 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Profit After Tax high stood at $59.6 million for Q2 2025, and its period low was -$27.4 million during Q1 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' median Profit After Tax value was -$5.7 million (recorded in 2023), while the average stood at $782421.1.
  • In the last 5 years, Rigel Pharmaceuticals' Profit After Tax plummeted by 16948.1% in 2022 and then skyrocketed by 588766.99% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Profit After Tax (Quarter) stood at -$22.6 million in 2021, then soared by 106.19% to $1.4 million in 2022, then plummeted by 47.39% to $737000.0 in 2023, then surged by 1845.86% to $14.3 million in 2024, then surged by 94.55% to $27.9 million in 2025.
  • Its Profit After Tax was $27.9 million in Q3 2025, compared to $59.6 million in Q2 2025 and $11.4 million in Q1 2025.